Eshwar Karra, CEO – Kotak Special Situations Fund at Kotak Investment Advisors said, We are delighted to partner with Biocon and this acquisition financing supports Biocon’s journey of becoming a world leading, fully integrated biosimilars enterprise.
Madhusudan Kela’s portfolio: 7 stocks rally up to 135% in CY26
Madhusudan Kela’s disclosed portfolio of 19 stocks was worth about Rs 2,665 crore as of August 14. Seven holdings gained 10–135% in 2026, while five